Pathogenesis of primary varices und recurrent varicose veins at the sapheno-femoral junction: The role of VEGF and VEGF-receptor;Pathogenese der primär- und rezidivvarikosis an der magna-krosse: Die rolle von VEGF und VEGF-rezeptor

Phlebologie

Volumn 36, Issue 3, 2007, Pages 137-142

  Rewerk, Stephan ^a   Noppeney, T ^c   Winkler, M ^c   Willeke, F ^b   Duczek, C ^a   Meyer, A J ^a   Gruber, A ^a   Grobholz, R ^a   Niedergethmann, K ^a   Niedergethmann, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b St Marien Krankenhaus Siegen gem GmbH   (Germany)

^c Gefäßzentrum Nürnberg   (Germany)

Author keywords

Neovascularisation; Pathogenesis; Varicogenesis; Vascular endothelial growth factor; VEGF; VEGF receptor

Indexed keywords

ANTIBODY; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; COMPARATIVE STUDY; CONTROL GROUP; FEMORAL VEIN; HUMAN; IMMUNOHISTOCHEMISTRY; INGUINAL REGION; NEOVASCULARIZATION (PATHOLOGY); PATHOGENESIS; RECURRENT DISEASE; REVIEW; SAPHENOUS VEIN; SCAR; STAIN; STATISTICAL SIGNIFICANCE; VARICOSIS;

EID: 34547124560     PISSN: 0939978X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1622176     Document Type: Review

References (35)

1. Badier-Commander C, Couvelard A, Henin D et al. Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. J Pathol 2001; 193: 398-407.
2. Bates DO, Hillman NJ, Williams B et al. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002; 200: 581-597.
3. Breier G. Functions of the VEGF/VEGF receptor system in the vascular system. Semin Thromb. Hemost 2000; 26: 553-559.
4. Breslow NE. Analysis of survival data under the proportional hazards model. Int Stat Rev 1975; 43: 45-58.
5. Couvelard A, O'Toole D, Leek R et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005; 46: 668-676.
6. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploition. Eur J Cancer 2000; 36: 1649-1660.
7. Fischer R, Kluess HG, Frings N et al. Der aktuelle Stand der Magnakrossenrezidiv-Forschung. Phlebologie 2003; 32: 54-59.
8. Fischer R, Linde N, Duff C et al. Late recurrent saphenofemoral junction reflux after ligation and stripping of greater saphenous vein. J Vasc Surg 2001; 34: 236-240.
9. Fischer R, Linde N, Duff C et al. Das Krosserezidiv - eine Nachkontrolle nach 34 Jahren. Phlebologie 2000; 29: 17-22.
10. Frings N, Nelle A, Tran P et al. Reduction of neoreflux after correctly performed ligation of the saphenofemoral junction. A randomized trial. Eur J Vasc Endovasc Surg 2004; 28: 246-252.
11. Frings N, Nelle A, Tran VTP et al. Unvermeidbares Rezidiv und Neoreflux nach korrekter Venasaphena-magna-Krossektomie: Neovaskularisation? Phlebologie 2003; 32: 96-100.
12. Frings N, Tran VTP, Nelle A et al. Krossenrezidiv der V Saphena magna trotz korrekter Krossektomie: Neoangiogenese. Phlebologie 1999; 28: 144-148.
13. Glass GM. Neovascularization in recurrence of the varicose great saphenous vein following transaction. Phlebology 1987; 2: 81-91.
14. Glass GM. Neovascularization in recurrent sapheno-femoral incompetence of varicose veins: surgical anatomy and morphology. Phlebology 1995; 10: 136-142.
15. Hoeben A, Landuyt B, Highley MS et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56: 549-580.
16. Hollingsworth SJ, Powell G, Barker SG et al. Primary varicose veins: altered transcription of VEGF and its receptors (KDR, fit-1, soluble fit-1) with sapheno-femoral junction incompetence. Eur J Vasc Endovasc Surg 2004; 27: 259-268.
17. Hollingsworth SJ, Tang CB, Dialynas M et al. Varicose veins: loss of release of vascular endothelial growth factor and reduced plasma nitric oxide. Eur J Vasc Endovasc Surg 2001; 22: 551-556.
18. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312.
19. Langenbeck B. Beiträge zur chirurgischen Pathologie der Venen. Arch Klin Chir 1861; 8: 1-80.
20. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
21. Montesano R. 1992 Mack Forster Award Lecture. Review. Regulation of angiogenesis in vitro. Eur J Clin Invest 1992; 22: 504-515.
22. Mumme A, Olbrich S, Barbera L et al. Validität der makroskopischen Identifikation von Neovaskulaten durch den Operateur. Phlebologie 2003; 32: 143-146.
23. Nyamekye I, Shepard NA, Davies B et al. Clinicopathological evidence that neovascularisation is a cause of recurrent varicose veins. Eur J Vasc Endovasc Surg 1998; 15: 412-415.
24. Pirk O. Viel Geld für nichts? Teures Krankheitsbild Ulcus cruris. Deutsches Ärzteblatt 2000; 97: A2992-2994.
25. Rabe E, Pannier-Fischer F, Bromen K et al. Bonner Venenstudie der Deutschen Gesellschaft für Phlebologie. Epidemiologische Untersuchung zur Frage der Häufigkeit und Ausprägung von chronischen Venenkrankheiten in der städtischen und landlichen Wohnbevölkerung. Phlebologie 2003; 32: 1-14.
26. Rewerk S, Duczek C, Gruber A et al. Die Rolle von VEGF und S100-Färbung bei Entstehung und Nachweis der Rezidivvarikosis. Phlebologie 2005; 34: A26.
27. Rewerk S, Duczek C, Gruber A et al. Role of vascular endothelial growth factor and S100 expression in development and detection of recurrent varicose veins. International Angiology 2005; 24 (Suppl 1): 101.
28. th World Congress. Union Internationale de Phlebologie. Rio (Brazil), October 2-7. Bologna: Medimond International Proceedings 2005; 27-30.
29. Rewerk S, Noppeney T, Winkler M et al. Venoneuronale De- und Regeneration bei Varikogenese und Neovaskularisation. Einfluss von Nerve Growth Factor. Phlebologie 2007; 36: 8-16.
30. Rewerk S, Nüllen H, Winkler M et al. Nervenfasern in Exzisaten von Rezidivvarizen. Der Wert der S100-Fürbung. Phlebologie 2005; 34: 299-304.
31. Rewerk S, Riester T, Winkler M et al. The function of VEGF (vascular endothelial growth factor) and the importance of S100-staining for real neovascularization as a cause of recurrent varicose veins in the groin. Langenbeck's Arch Surg 2005; 390: 481.
32. Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 2005; 128: 303-309.
33. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor (VPF) that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
34. Shoab SS, Scurr JH, Coleridge-Smith PD. Increased plasma vascular endothelial growth factor among patients with chronic venous disease. J Vasc Surg 1998; 28: 535-40.
35. Tsuzuki Y, Fukumura D, Oosthuyse B et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1 alpha hypoxia response element VEGF cascade differently regulates vascular response and growth rate in tumors. Cancer Res 2000; 60: 6248-6252.